>
Switch to:

Creative Medical Technology Holdings Debt-to-EBITDA

: -0.02 (As of Jun. 2021)
View and export this data going back to 2009. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Creative Medical Technology Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $0.22 Mil. Creative Medical Technology Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $0.00 Mil. Creative Medical Technology Holdings's annualized EBITDA for the quarter that ended in Jun. 2021 was $-10.59 Mil. Creative Medical Technology Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2021 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Creative Medical Technology Holdings's Debt-to-EBITDA or its related term are showing as below:

OTCPK:CELZ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.95   Med: -0.2   Max: -0.02
Current: -0.02

-7.95
-0.02

During the past 13 years, the highest Debt-to-EBITDA Ratio of Creative Medical Technology Holdings was -0.02. The lowest was -7.95. And the median was -0.20.

OTCPK:CELZ's Debt-to-EBITDA is ranked lower than
99.99% of the 27 Companies
in the Biotechnology industry.

( Industry Median: 1.85 vs. OTCPK:CELZ: -0.02 )

Creative Medical Technology Holdings Debt-to-EBITDA Historical Data

The historical data trend for Creative Medical Technology Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Creative Medical Technology Holdings Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Debt-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 -0.22 -0.06 -0.16 -0.02

Creative Medical Technology Holdings Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 0.32 -0.01 - -0.02

Competitive Comparison

For the Biotechnology subindustry, Creative Medical Technology Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Creative Medical Technology Holdings Debt-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Creative Medical Technology Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Creative Medical Technology Holdings's Debt-to-EBITDA falls into.



Creative Medical Technology Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Creative Medical Technology Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2020 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.789 + 0) / -35.029
=-0.02

Creative Medical Technology Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.222 + 0) / -10.592
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2021) EBITDA data.


Creative Medical Technology Holdings  (OTCPK:CELZ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Creative Medical Technology Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Creative Medical Technology Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Creative Medical Technology Holdings Business Description

Creative Medical Technology Holdings logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
N/A
Address
211 E Osborn Road, Phoenix, AZ, USA, 85012
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid-derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
Executives
Ichim Thomas director 2027 E. CEDAR ST. TEMPE AZ 85281
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)